SURPASS trial programme: difference between revisions
Diff·revision 17 → 18·23:54, 18 Apr 2025
Difference between revision 17 and revision 18 of SURPASS trial programme. 6 lines changed; the page grew by 516 bytes.
| Revision 17 — 22:12, 26 Mar 2025 LeaderLoic (talk) close an unbalanced quotation mark 3,958 bytes ±0 | Revision 18 — 23:54, 18 Apr 2025 AppendixAlva (talk) expand §The head-to-head comparison 4,474 bytes +516 | ||
|---|---|---|---|
| 34 | Cross-trial comparison of SURMOUNT-1 with STEP 1 is made constantly and is not sound: the populations, durations, escalation schedules and lifestyle interventions differ.{{r|ich_e9}} | 34 | Cross-trial comparison of SURMOUNT-1 with STEP 1 is made constantly and is not sound: the populations, durations, escalation schedules and lifestyle interventions differ.{{r|ich_e9}} |
| 35 | 35 | ||
| + | 36 | == What the programme establishes == | |
| + | 37 | It establishes glycaemic efficacy in type 2 diabetes across a range of background therapies, superiority to the specific comparators at the specific doses studied, and the adverse-effect profile at those doses.{{r|frias2021}} | |
| + | 38 | ||
| + | 39 | It does not establish superiority at maximal doses of the comparators, nor efficacy or safety in populations outside those studied, nor cardiovascular superiority — SURPASS-CVOT was designed against an active comparator. | |
| + | 40 | ||
| 36 | == References == | 41 | == References == |
| 37 | {{reflist}} | 42 | {{reflist}} |
| ⋮ | ⋮ | ||
| 45 | * [[Semaglutide]] | 50 | * [[Semaglutide]] |
| 46 | * [[SUSTAIN trial programme]] | 51 | * [[SUSTAIN trial programme]] |
| + | 52 | * [[Dual incretin agonist]] | |
| 47 | 53 | ||
| 48 | {{DEFAULTSORT:SURPASS trial programme}} | 54 | {{DEFAULTSORT:SURPASS trial programme}} |